Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-22-Speech-2-014"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20021022.1.2-014"2
lpv:hasSubsequent	lp_eu:2002-10-22-Speech-2-0152
lpv:speaker	lp:Jules Maaten2
lpv:spokenAs	unknown; Volkspartij voor Vrijheid en Democratie (1999-07-20--2004-07-19)3 member_of_the_bureau; ELDR (2002-03-07--2004-07-19)3 member; Delegation for relations with the Member States of ASEAN, south-east Asia and the Republic of Korea (2002-02-07--2004-07-19)3 substitute; Committee on Foreign Affairs, Human Rights, Common Security and Defence Policy (2002-01-17--2004-07-19)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3
lpv:translated text	"Mr President, in its proposal, the Commission has tried to reform the pharmaceutical industry, or at least has tried to make a start on it. In the pharmaceutical industry, Europe is losing out to the United States. It is not for nothing that an increasing number of companies have decided to carry out their practical research and development in the United States. European legislation is too opaque, which dampens the companies' motivation to carry out their activities in Europe, and in order to counter this, better European coordination in this field is therefore necessary as a matter of priority. I am greatly in favour of opening up this fossilised market. We must therefore strive for more competition within the European market, and one of the ways of achieving this is, for example, by making generic medicines available sooner, something on which a sound compromise has been reached within the Committee on the Environment, Public Health and Consumer Policy. Furthermore, I would insist on the centralised procedure, which is carried out by the Agency for the Evaluation of Medicinal Products in London, being reinforced so as to guarantee the equal treatment of all pharmaceutical companies and to give patients throughout Europe access to the same medicines. This centralised method also promotes all the objectives pursued by the Commission, such as a high level of health care, completion of the internal market, more transparency, improvement of competition and preparation for enlargement. I also set great store by the provision of information. It remains a mystery to me why the pharmaceutical industry is not allowed to inform patients about its products. I have said it before, but I should like to repeat it here: the European Union has thus been taken over by events and is discriminating against patients. At the moment, information of this kind is only available to people with a command of English and with access to the Internet, as this information available in the United States. Patients who have no access to these resources are kept in the dark by Europe, and it is for this reason too that I think that the Commission's proposal to come up with a trial project is sound and is in any case a good first step. I do believe that by only making information on asthma, AIDS and diabetes available, patients suffering from other diseases are discriminated against, and I would call for this list to be extended. Finally, I should like to remark that the reinforcement of the role of patient organisations in this context is of course important at European level as well, including with a view to enlargement and to this centralised procedure. The Group of the Greens has tabled amendments to this effect, which I should like to endorse."@en1
lpv:unclassifiedMetadata	"is"1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph